These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
13. Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. Patterson LH; McKeown SR; Robson T; Gallagher R; Raleigh SM; Orr S Anticancer Drug Des; 1999 Dec; 14(6):473-86. PubMed ID: 10834269 [TBL] [Abstract][Full Text] [Related]
14. In vitro cytotoxicity following specific activation of amygdalin by beta-glucosidase conjugated to a bladder cancer-associated monoclonal antibody. Syrigos KN; Rowlinson-Busza G; Epenetos AA Int J Cancer; 1998 Dec; 78(6):712-9. PubMed ID: 9833764 [TBL] [Abstract][Full Text] [Related]
17. Prodrug activation enzymes in cancer gene therapy. Aghi M; Hochberg F; Breakefield XO J Gene Med; 2000; 2(3):148-64. PubMed ID: 10894261 [TBL] [Abstract][Full Text] [Related]
18. Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Roy P; Waxman DJ Toxicol In Vitro; 2006 Mar; 20(2):176-86. PubMed ID: 16293390 [TBL] [Abstract][Full Text] [Related]
19. Engineering a thermostable human prolyl endopeptidase for antibody-directed enzyme prodrug therapy. Heinis C; Alessi P; Neri D Biochemistry; 2004 May; 43(20):6293-303. PubMed ID: 15147213 [TBL] [Abstract][Full Text] [Related]
20. Systems biology and the mathematical modelling of antibody-directed enzyme prodrug therapy (ADEPT). Varner JD Syst Biol (Stevenage); 2005 Dec; 152(4):291-302. PubMed ID: 16986273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]